Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma

Mike Berry, Angela Morgan, Dominick E Shaw, Deborah Parker, Ruth Green, Christopher Brightling, Peter Bradding, Andrew J Wardlaw, Ian D Pavord

Background: Non-eosinophilic asthma is a potentially important clinicopathological phenotype since there is evidence that it responds poorly to inhaled corticosteroid therapy. However, little is known about the underlying airway immunopathology and there are no data from placebo-controlled studies examining the effect of inhaled corticosteroids.

Methods: Airway immunopathology was investigated using induced sputum, bronchial biopsies, bronchial wash and bronchoalveolar lavage in 12 patients with symptomatic eosinophilic asthma, 11 patients with non-eosinophilic asthma and 10 healthy controls. The patients with non-eosinophilic asthma and 6 different patients with eosinophilic asthma entered a randomised, double-blind, placebo-controlled crossover study in which the effects of inhaled mometasone 400 μg once daily for 8 weeks on airway responsiveness and asthma quality of life were investigated.

Results: Patients with non-eosinophilic asthma had absence of eosinophils in the mucosa (median 4.4 cells/mm² vs 23 cells/mm² in eosinophilic asthma and 0 cells/mm² in normal controls; p = 0.03) and normal subepithelial layer thickness (5.8 μm vs 10.3 μm in eosinophilic asthma and 5.1 μm in controls, p = 0.002). Non-eosinophilic and eosinophilic asthma groups had increased mast cell numbers in the airway smooth muscle compared with normal controls (9 vs 8 vs 0 cells/mm², p = 0.016). Compared with placebo, 8 weeks of treatment with inhaled mometasone led to less improvement in methacholine PC₂₀ (0.5 vs 5.5 doubling concentrations, 95% CI of difference 0.27 to 1.43; p = 0.008) and asthma quality of life (0.2 vs 1.0 points, 95% CI of difference 0.27 to 1.43; p = 0.008).

Conclusions: Non-eosinophilic asthma represents a pathologically distinct disease phenotype which is characterised by the absence of airway eosinophilia, normal subepithelial layer thickness and a poor short-term response to treatment with inhaled corticosteroids.

Clinicians have long regarded asthma as a heterogeneous disease, although detailed clinicopathological studies have tended to emphasise the similarities in the underlying airway pathology and disordered function between patients. The development of safe non-invasive induced sputum techniques has provided the opportunity to study airway inflammation in a diverse range of patients. Using this technique, we and a number of other groups have identified a subset of adults who have clear physiological evidence of asthma but no induced sputum evidence of eosinophilic airway inflammation. This asthma phenotype is potentially clinically important since several uncontrolled studies have suggested that it is associated with a poor short-term and longer-term response to inhaled corticosteroids.

Several studies have noted that an airway neutrophilia is often present in patients with non-eosinophilic asthma, and Wenzel et al reported a predominantly neutrophilic airway inflammatory response with an absence of eosinophils and normal basement membrane thickness in a subgroup of patients with refractory asthma from whom bronchial biopsy specimens were taken. These findings support the concept that non-eosinophilic asthma is a pathologically distinct entity, although the extent to which these findings reflect the effects of treatment remains unclear.

The aim of this study was to compare the immunopathology of eosinophilic and non-eosinophilic asthma with normal controls in patients with symptomatic asthma who were not treated with inhaled corticosteroids. We also set out to compare the response to 8 weeks of treatment with the inhaled corticosteroid mometasone in a prospective randomised, double-blind, placebo-controlled crossover trial in patients with non-eosinophilic asthma and in a subgroup with eosinophilic asthma.

METHODS

Subjects

Subjects were recruited from Glenfield Hospital clinics and by local paper advertisement. All subjects with asthma had participated in a recent longitudinal study of patients with severe asthma, the absence of sputum eosinophils has been reported to be a stable feature in a number of patients observed over 12 months; another study showed that it was present in untreated symptomatic patients as well as those receiving inhaled corticosteroid therapy. These observations suggest that, in some patients at least, non-eosinophilic asthma is a stable phenotype that is not solely explained by the effects of corticosteroid therapy.
symptoms of episodic cough, wheeze or breathlessness such that their Juniper asthma control score was >1.57 points, a level which is consistent with the Global Initiative for Asthma (GINA) recommendations for an increase in treatment. Subjects had at least one of the following objective measures of airway hyperresponsiveness and/or variable airflow obstruction: concentration of methacholine provoking a 20% fall in forced expiratory volume in 1 s (FEV₁ PC₂₀) of <8 mg/ml, increase in FEV₁ of 15% or greater following inhalation of 200 μg salbutamol and/or peak flow amplitude as percentage of mean over 14 days of >20%. Patients with eosinophilic asthma were recruited in two separate groups, one for the bronchoscopy study and one for the placebo-controlled study (fig 1). Normal control subjects had no respiratory symptoms, normal spirometric values and a methacholine PC₂₀ of >16 mg/ml.

Non-eosinophilic asthma was diagnosed in patients who had a sputum eosinophil count below our normal range (1.9%) on at least two occasions separated by 1 month while still symptomatic with a Juniper asthma control score of >1.57 points and while not receiving inhaled or oral corticosteroids. All patients with non-eosinophilic asthma had no evidence of bronchiectasis on a high-resolution CT scan. Patients who had symptoms due to rhinitis and gastro-oesophageal reflux disease were excluded. Our criteria for identifying these symptoms has been previously described. None of the patients had ever smoked, had a respiratory tract infection within 6 weeks of recruitment or had received inhaled or oral corticosteroids for 3 months before entering the study.

The Leicestershire and Rutland ethics committee approved the study and all patients provided informed written consent. T cells from bronchoalveolar lavage (BAL) fluid from some of the subjects in this study were used in a separate study.

Measurements

Single flow nitric oxide was recorded at 50 ml/s as previously described. Spirometric parameters were measured using a rolling seal spirometer (Vitalograph, UK). The methacholine PC₂₀ was measured using the tidal breathing method with a maximum inhaled concentration of 16 mg/ml, as previously described. Methacholine PC₂₀ was calculated by linear interpolation of the change in FEV₁/concentration of methacholine on a log dose-response curve as the inhaled concentration of methacholine causing a 20% reduction in FEV₁. Change in methacholine PC₂₀ was expressed in doubling concentrations.

A symptom visual analogue score was measured using three 100 mm scales representing cough, wheeze and breathlessness. Asthma quality of life was measured using the Juniper asthma quality of life score. Sputum induction was performed and samples were processed as previously described.

Sputum levels of interleukin (IL)-8, cysteinyl leucotrienes and histamine were measured using standard ELISA kits (BD Pharmagen, Immunotech and Cayman Chemicals, respectively) and eosinophilic cationic protein (ECP) was measured using a fluorescence immunoassay (UniCAP test, Pharmacia, Uppsala, Sweden). These assays have been previously validated for use in sputum supernatants. The sensitivity levels of the assays were 2, 13 × 10⁻³, 0.8 × 10⁻³ and 50 × 10⁻³ ng/ml for ECP, cysteinyl leucotrienes, IL-8 and histamine. The intra-assay coefficient of variability was 5–10% and the interassay coefficient of variability was 3–15% across a range of concentrations of mediators measured.

Bronchoscopy was performed according to British Thoracic Society guidelines. 20 ml of warmed sterile saline solution was instilled into the bronchus intermedius, aspirated and analysed as the wash sample. Three sequential samples of 60 ml warmed sterile saline solution were then instilled into the middle lobe bronchus and aspirated; the pooled aspirate from these samples was analysed as the BAL fluid. Biopsy specimens were taken from the middle and right lower lobe carinae.

The BAL fluid and bronchial wash aspires were filtered through 48 μm gauze and diluted to a cell concentration of 0.3 × 10⁶ cells per/ml for cytopsins and 5 × 10⁶ cells per/ml for cell counts.
flow cytometry. Cytospins were made with 75 μl aspirate and stained with Romanowsky stain before being counted by a person blind to the details of the subjects. Cell counts were given as a percentage of at least 400 inflammatory cells counted. Flow cytometry was used to measure CD4, CD8, IL-4 and interferon gamma (IFNγ) on CD3 positive lymphocytes from peripheral blood and BAL fluid cells using commercially available antibodies as previously described.17 IL-4 and IFNγ were measured using intracellular staining following stimulation for 4 h with phorbil 12-myristate 13-acetate (PMA) and calcium ionophore as previously described.

Processing of biopsy specimens
Biopsy specimens were taken from the middle and right lower lobe carinae and fixed by immediately being placed in ice cold acetone containing the protease inhibitor phenylmethansulfonyl fluoride (PMSF) (2 mM) and maintained at −20°C for 24 h. The fixative was then replaced first with water-free acetone and then with methyl benzoate for 15 min at room temperature. The biopsy specimens were then placed in 5% methyl benzoate in glycol methacrylate (GMA solution A, 250 μl GMA solution B (Polysciences) and 45 mg benzoyl peroxide (Polysciences), replacing the lid to expel any air. Specimens were left to polymerise overnight at 4°C and then stored with silica gel at air. Specimens were left to polymerise overnight at 4˚C and benzoyl peroxide (Polysciences), replacing the lid to expel any

Table 1 Clinical characteristics of patients with eosinophilic asthma, non-eosinophilic asthma and normal controls

<table>
<thead>
<tr>
<th></th>
<th>Normal controls</th>
<th>Eosinophilic asthma</th>
<th>Non-eosinophilic asthma</th>
<th>p Value (ANOVA)</th>
<th>p Value (eosinophilic vs non-eosinophilic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (men)</td>
<td>10 (5)</td>
<td>12 (8)</td>
<td>11 (3)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Age (years)</td>
<td>41 (22–61)</td>
<td>42 (27–69)</td>
<td>47 (19–68)</td>
<td>0.65</td>
<td>–</td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td>105 (3.9)</td>
<td>90.3 (6.2)</td>
<td>88 (4.9)</td>
<td>0.05</td>
<td>0.96</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>82 (1.8)</td>
<td>73.9 (2.9)</td>
<td>69 (5.6)</td>
<td>0.025</td>
<td>0.58</td>
</tr>
<tr>
<td>β2 agonist reversibility (%)</td>
<td>1.1 (0.9)</td>
<td>9.5 (2.3)</td>
<td>12.7 (3.4)</td>
<td>0.001</td>
<td>0.67</td>
</tr>
<tr>
<td>Methacholine PC20 (mg/ml)</td>
<td>&gt;16</td>
<td>0.67 (0.2)</td>
<td>0.83 (0.2)</td>
<td>&lt;0.001</td>
<td>0.15</td>
</tr>
<tr>
<td>Ateopic (%)</td>
<td>2 (20)</td>
<td>8 (66)</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

Data given as mean (SE) except age which is given as mean (range) and methacholine PC20 which is given as geometric mean (log SE). FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; β2 agonist reversibility, percentage increase in FEV1 following inhalation of 200 μg salbutamol; methacholine PC20, concentration of inhaled methacholine which causes a 20% fall in FEV1.
between groups by unpaired t tests; the period and order effect were analysed by analysis of covariance (ANCOVA). Secondary outcome measures were net change in post-bronchodilator FEV₁, symptom visual analogue scale, exhaled nitric oxide concentration, sputum eosinophil count and sputum neutrophil count. This study was analysed as a mechanistic study and only data from patients who completed both treatment phases were analysed. We chose methacholine PC₂₀ as a co-primary outcome as it was the most responsive outcome measure in an earlier study. Asthma quality of life was chosen as a second primary outcome as it was obtained from a co-primary outcome as it was the most responsive outcome measure in an earlier study. Asthma symptom visual analogue score, exhaled nitric oxide concentration, ratio of FEV₁ to forced vital capacity (FVC) and CD₈ ratio between the groups.

### RESULTS

The characteristics of the study subjects are given in table 1. Patients with asthma had a significantly lower FEV₁ (percentage predicted), ratio of FEV₁ to forced vital capacity (FVC) and methacholine PC₂₀ and significantly higher B₂ reversibility than normal controls. There was no difference between eosinophilic and non-eosinophilic asthma. No patients classified as having non-eosinophilic asthma at the first visit developed a sputum eosinophilia (>1.9%) at the second visit or at any other point during the investigation.

### Immunopathology study

Patients with non-eosinophilic asthma had lower sputum eosinophil counts, bronchial wash eosinophil counts and BAL fluid eosinophil counts than patients with eosinophilic asthma (table 2). There was no significant difference between sputum, bronchial wash and BAL fluid neutrophil counts, although a trend towards higher sputum neutrophil counts in non-eosinophilic asthma was noted (table 2). There was no difference in the percentage of BAL fluid lymphocytes positive for IL-4 or IFNγ, or in the blood or BAL fluid lymphocyte CD4/CD8 ratio between the groups.

Following embedding, cutting and staining, adequate biopsies suitable for counting were obtained from the following number of normal controls, patients with eosinophilic asthma and patients with non-eosinophilic asthma: submucosa (9, 7, 10), airway smooth muscle (5, 7, 6) and subepithelial layer (7, 11, 7). There were no significant differences in the clinical characteristics of patients from whom adequate biopsies were obtained and those from whom they were not. Patients with eosinophilic asthma had a median (distance) of 23 (29) bronchial submucosal cells positive for major basic protein per mm² which was higher than both normal controls (0 (9.4) cells/mm²) and patients with non-eosinophilic asthma (4.4 (7.9) cells/mm²; p = 0.03, fig 2A). There was no significant difference between the groups in the number of submucosal cells positive for tryptase (13 (5.7) vs 11 (15) vs 22 (33) cells/mm²; p = 0.52); however, the number of tryptase positive cells in the airway smooth muscle was increased in patients with eosinophilic asthma (8 (12) cells/mm²) and those with non-eosinophilic asthma 9 (56) cells/mm² compared with normal controls (0 (1.8) cells/mm²; p = 0.016, fig 2B). There were no significant differences in the number of submucosal cells positive for neutrophil elastase. The subepithelial layer thickness was 10.3 (3.1) μm in patients with eosinophilic asthma compared with 5.8 (3.0) μm in those with non-eosinophilic asthma and 5.1 (2.1) μm in normal controls (p = 0.002, fig 2C). The sputum supernatant IL-8 concentration was significantly lower in patients with non-eosinophilic asthma than in normal controls and patients with eosinophilic asthma (table 2).

### Placebo-controlled study

One patient with non-eosinophilic asthma withdrew from the study after bronchoscopy because of work commitments. No patients withdrew from this part of the study after enrolment. Treatment period or order did not influence values before treatment or the change in primary outcome measures. Compared with placebo, 8 weeks of treatment with inhaled mometasone led to a net doubling concentration improvement in methacholine PC₂₀ of 5.5 (95% CI 2.0 to 9.0; p = 0.01) in patients with eosinophilic asthma and 0.5 (95% CI −2.4 to 3.3; p = 0.72) in the non-eosinophilic asthma group (mean difference 5.1 doubling doses, 95% CI 1.1 to 9.1; p = 0.018). There was a net improvement in Juniper asthma quality of life of 1.0 points (95% CI 0.5 to 1.5; p = 0.004) following treatment with inhaled mometasone compared with placebo in the eosinophilic asthma group and of 0.2 points (95% CI −0.3 to 0.6; p = 0.43) in the non-eosinophilic asthma group (mean difference 0.9, 95% CI 0.27 to 1.43; p = 0.008, fig 3).

Secondary outcome measures are given in table 3.

### Table 2: Inflammatory characteristics of patients with eosinophilic asthma, non-eosinophilic asthma and normal controls

<table>
<thead>
<tr>
<th></th>
<th>Normal controls</th>
<th>Eosinophilic asthma</th>
<th>Non-eosinophilic asthma</th>
<th>p Value (ANOVA/KW)</th>
<th>p Value (eosinophilic vs non-eosinophilic asthma)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sputum eosinophil count (%^ {†} ^ {‡} )</td>
<td>0.26 (0.1)</td>
<td>4.0 (1.0)</td>
<td>0.65 (0.1)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sputum neutrophil count (%)</td>
<td>31.6 (6.9)</td>
<td>38.3 (7.9)</td>
<td>76.2 (9.0)</td>
<td>0.06</td>
<td>–</td>
</tr>
<tr>
<td>Sputum IL-8 (ng/ml)^ {‡} ^</td>
<td>26.7 (38)</td>
<td>34.0 (44)</td>
<td>9.31</td>
<td>0.016</td>
<td>0.06</td>
</tr>
<tr>
<td>Sputum ECP (μg/ml)^ {‡} ^</td>
<td>75.2 (425)</td>
<td>378 (1075)</td>
<td>105 (133)</td>
<td>0.055</td>
<td>–</td>
</tr>
<tr>
<td>Sputum Cys-LT (ng/ml)^ {†} ^</td>
<td>743 (288)</td>
<td>1073 (2255)</td>
<td>636 (441)</td>
<td>0.047</td>
<td>0.37</td>
</tr>
<tr>
<td>Sputum histamine (ng/ml)^ {‡} ^</td>
<td>7.2 (17)</td>
<td>32 (53)</td>
<td>11.9 (27)</td>
<td>0.193</td>
<td>–</td>
</tr>
<tr>
<td>Bronchial wash eosinophil count (%)</td>
<td>0.6 (0.2)</td>
<td>2.0 (0.2)</td>
<td>0.4 (0.3)</td>
<td>0.017</td>
<td>0.017</td>
</tr>
<tr>
<td>Bronchial wash neutrophil count (%)</td>
<td>27.4 (6.3)</td>
<td>25.1 (5.0)</td>
<td>27.9 (6.7)</td>
<td>0.94</td>
<td>–</td>
</tr>
<tr>
<td>BAL eosinophil count (%)</td>
<td>0.6 (0.2)</td>
<td>1.4 (0.1)</td>
<td>0.4 (0.1)</td>
<td>0.03</td>
<td>0.029</td>
</tr>
<tr>
<td>BAL neutrophil count (%)</td>
<td>14.7 (4.1)</td>
<td>7.2 (2.4)</td>
<td>8.4 (2.5)</td>
<td>0.19</td>
<td>–</td>
</tr>
<tr>
<td>BAL IL-4 (ng/l)</td>
<td>4.1 (1.2)</td>
<td>3.9 (1.3)</td>
<td>7.0 (2.3)</td>
<td>0.36</td>
<td>–</td>
</tr>
<tr>
<td>BAL IFNγ (% of CD3⁺ lymphocytes)</td>
<td>32.3 (9.6)</td>
<td>32.3 (8.6)</td>
<td>33.3 (5.7)</td>
<td>0.99</td>
<td>–</td>
</tr>
<tr>
<td>Submucosal MXP⁺ve cells/mm²^ {‡} ^</td>
<td>0.9 (9.4)</td>
<td>23 (29)</td>
<td>4.4 (7.9)</td>
<td>0.03</td>
<td>0.016</td>
</tr>
<tr>
<td>Submucosal IFNγ⁺ve cells/mm²^ {‡} ^</td>
<td>10 (31)</td>
<td>10 (24)</td>
<td>9 (22)</td>
<td>0.18</td>
<td>–</td>
</tr>
<tr>
<td>Submucosal tryptase⁺ve cells/mm²^ {‡} ^</td>
<td>13 (5.7)</td>
<td>11 (15)</td>
<td>22 (33)</td>
<td>0.52</td>
<td>–</td>
</tr>
<tr>
<td>Smooth muscle tryptase⁺ve cells/mm²^ {‡} ^</td>
<td>0 (1.8)</td>
<td>8 (12)</td>
<td>9 (56)</td>
<td>0.016</td>
<td>0.2</td>
</tr>
<tr>
<td>Subepithelial layer thickness (μm)^ {‡} ^</td>
<td>5.1 (2.1)</td>
<td>10.3 (3.1)</td>
<td>5.8 (3.0)</td>
<td>0.002</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Data given as mean (SE) except *median (interquartile distance) and †geometric mean (log SE).

IL, interleukin; ECP, eosinophil cationic protein; Cys-LT, cysteinyl leukotriene; BAL, bronchoalveolar lavage; IFNγ, interferon γ; MXP, major basic protein; NE, neutrophil elastase; ANOVA, analysis of variance; KW, Kruskal-Wallis.
DISCUSSION

We describe 12 patients with symptomatic asthma who had a distinct sputum and bronchial biopsy pattern characterised by the absence of eosinophilic airway inflammation and a normal subepithelial layer thickness. In common with previous reports, patients tended to be non-atopic middle aged women. Some had sputum evidence of neutrophilic airway inflammation, although increased neutrophil numbers were not evident in bronchoscopy samples. Importantly, 8 weeks of treatment with inhaled mometasone had no significant effect on airway responsiveness and asthma quality of life compared with placebo. This was in contrast to findings in patients with asthma and eosinophilic airway inflammation where inhaled steroids were associated with a marked improvement in these measures.

Our patients were sufficiently symptomatic to warrant an increase in treatment based on their Juniper asthma control score and all had clear objective evidence of asthma, so the absence of eosinophilic airway inflammation seen in our patients does not reflect remission of underlying disease. Indeed, they had more symptoms than the patients with eosinophilic asthma who participated in the double-blind placebo-controlled study. The absence of sputum eosinophils was evident before entry into the study and was a consistent feature during the study. No patients with non-eosinophilic asthma had evidence of eosinophilic airway inflammation on bronchoscopy or in the six sputum tests done throughout the study, five of which were done off inhaled corticosteroids. These observations support the hypothesis that non-eosinophilic asthma represents a stable clinical phenotype which is not solely explained by the effects of treatment.\(^{11}\) Our finding of a normal subepithelial layer thickness in our patients with non-eosinophilic asthma is consistent with the finding by Wenzel and colleagues in severe asthma.\(^{7}\) The fact that thickening of the subepithelial layer is found in patients with rhinitis and in patients with eosinophilic bronchitis without asthma and not in those with non-eosinophilic asthma suggests that this finding may be related to eosinophilic airway inflammation rather than asthma per se. Longitudinal studies have suggested that increased subepithelial layer thickness is a longer term marker of eosinophilic airway inflammation than cell counts,\(^{22}\) so the observation that subepithelial layer thickness is normal in non-eosinophilic asthma increases our confidence that the absence of eosinophilic airway inflammation is a stable feature.

We acknowledge that our biopsy study observations were made on a small number of patients and that we did not adjust for multiple comparisons. Our findings should therefore be regarded as hypothesis-generating rather than definitive. However, biopsies were examined blind to patient status and the magnitude and consistency of the effect makes a chance finding unlikely.

The cause of airway inflammation was not specifically investigated in our study. None of the patients had CT evidence of bronchiectasis, symptoms to suggest recent respiratory tract infection or a significant smoking history, and atopy was unusual. The association with female gender and onset of symptoms in middle age is similar to observations made in chronic cough,\(^{23}\) and it is possible that there are some similarities between these conditions. Other studies have reported increased sputum neutrophil counts and IL-8 concentrations\(^ {6}\) and have speculated that the inflammatory response is due to stimuli such as environmental endotoxin, viral infection or ozone leading to activation of the innate immune system and consequent release of proinflammatory cytokines.\(^ {24}\) Our finding of a reduced IL-8 concentration in the sputum supernatants of patients with non-eosinophilic asthma was unexpected and in contrast to previously reported findings;\(^ {24}\) one possible explanation is that there are different types on non-eosinophilic asthma with varying degrees of neutrophilic inflammation.\(^ {25}\)

Perhaps the main point of interest in non-eosinophilic asthma is the suggestion that it represents a corticosteroid resistant form of the disease. Our study is the first double-blind randomised controlled trial to specifically compare the response to inhaled corticosteroids in eosinophilic and non-eosinophilic

---

Figure 2 Inflammatory cell counts in bronchial biopsy specimens from patients with eosinophilic asthma, non-eosinophilic asthma and normal controls.
Figure 3 Primary outcome measures in study of inhaled mometasone versus placebo in patients with eosinophilic and non-eosinophilic asthma. (A) Concentration of methacholine provoking a fall in FEV₁ of 20%. (B) Juniper asthma quality of life score. Open symbols indicate mean/geometric mean values.

Table 3 Clinical and inflammatory characteristics of patients before and after 8 weeks of treatment with inhaled mometasone 400 μg once daily and matched placebo.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Mometasone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methacholine PC_{20} (mg/ml)</td>
<td>1.53 (0.17)</td>
<td>0.16 (0.32)</td>
<td>0.46 (0.22)</td>
<td>2.13 (0.27)</td>
<td>1.42 (0.18)</td>
<td>1.07 (0.27)</td>
<td>1.69 (0.22)</td>
<td>1.74 (0.18)</td>
<td>0.72</td>
<td>0.018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma QOL score</td>
<td>5.5 (0.3)</td>
<td>5.5 (0.4)</td>
<td>5.6 (0.3)</td>
<td>6.6 (0.2)</td>
<td>0.004</td>
<td>5.0 (0.3)</td>
<td>5.0 (0.3)</td>
<td>5.1 (0.3)</td>
<td>5.2 (0.4)</td>
<td>0.43</td>
<td>0.008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (%)</td>
<td>94 (7.9)</td>
<td>93 (8.4)</td>
<td>94 (7.3)</td>
<td>94 (7.9)</td>
<td>0.62</td>
<td>86 (3.8)</td>
<td>84 (4.1)</td>
<td>87 (4.7)</td>
<td>82 (3.2)</td>
<td>0.46</td>
<td>0.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom VAS (mm)</td>
<td>59 (27)</td>
<td>76 (29)</td>
<td>28 (7.6)</td>
<td>12 (7.1)</td>
<td>0.33</td>
<td>141 (41)</td>
<td>122 (39)</td>
<td>151 (39)</td>
<td>115 (50)</td>
<td>0.79</td>
<td>0.82</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exhaled NO (ppb)*</td>
<td>56 (0.1)</td>
<td>79 (0.1)</td>
<td>65 (0.1)</td>
<td>21 (0.1)</td>
<td>0.003</td>
<td>13 (0.1)</td>
<td>15 (0.1)</td>
<td>13 (0.1)</td>
<td>11 (0.2)</td>
<td>0.14</td>
<td>0.003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alveolar NO (ppb)</td>
<td>9.2 (1.2)</td>
<td>12 (2.3)</td>
<td>5.7 (1.2)</td>
<td>4.3 (1.3)</td>
<td>0.27</td>
<td>3.2 (0.9)</td>
<td>2.4 (0.6)</td>
<td>3.1 (0.3)</td>
<td>3.9 (0.9)</td>
<td>0.64</td>
<td>0.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sputum eosinophils (%)</td>
<td>71 (0.1)</td>
<td>9.9 (0.1)</td>
<td>11 (0.2)</td>
<td>2.3 (0.2)</td>
<td>0.001</td>
<td>0.6 (0.2)</td>
<td>0.4 (0.2)</td>
<td>0.4 (0.2)</td>
<td>0.5 (0.1)</td>
<td>0.50</td>
<td>0.022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sputum neutrophils (%)</td>
<td>26 (5.6)</td>
<td>33 (7.2)</td>
<td>40 (8.9)</td>
<td>45 (11)</td>
<td>0.93</td>
<td>63 (7.7)</td>
<td>67 (7.6)</td>
<td>65 (5.7)</td>
<td>55 (6.7)</td>
<td>0.20</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data given as mean (SE) except *geometric mean (log SE).

FEV₁, forced expiratory volume in 1 s; PC_{20}, dose of inhaled methacholine causing a 20% fall in FEV₁; QOL, quality of life; VAS, visual analogue score; NO, nitric oxide; IL-8, interleukin-8; ECP, eosinophilic cationic protein; Cys-Lt, cysteinyl leukotriene.
Non-eosinophilic asthma

The observations were made on a small number of patients and there was a difference in baseline severity of symptoms and airway responsiveness between and within the group which could have compromised our results. In addition, the small sample size means that we had limited power to detect carry-over effects. However, there were clear differences in primary outcome measures that were above the level that the study was powered to detect, suggesting that they were real differences. The significantly reduced response to inhaled mometasone in patients with non-eosinophilic asthma compared with eosinophilic asthma is consistent with the findings of previous uncontrolled studies. In contrast to these findings, Godon et al found a similar response to inhaled corticosteroids in patients who were classified as eosinophilic or non-eosinophilic on the basis of a single sputum sample. However, these observations were based on an uncontrolled study in patients with symptomatic asthma who were recruited during a period of poor asthma control and it is possible that the improvement seen in patients with non-eosinophilic asthma reflected regression to the mean. In addition, patients were younger and more likely to be atopic than the patients with non-eosinophilic asthma identified by us, so it is possible that the populations were different.

Although our study showed a difference in response to inhaled corticosteroids in eosinophilic compared with non-eosinophilic asthma, we cannot conclude from our sample size that there is no significant response to inhaled mometasone in patients with non-eosinophilic asthma. Similarly, our study does not allow us to draw any conclusions about the long-term benefits of inhaled corticosteroids. However, an earlier 12 month study has suggested no increase in exacerbation frequency in non-eosinophilic asthma despite substantial reductions in the dose of oral and inhaled corticosteroids. Further appropriately powered studies should address this important question in more detail.

Our findings suggest that eosinophilic and non-eosinophilic asthma represent distinct clinical and pathological phenotypes. They provide further evidence against a causal relationship between eosinophilic airway inflammation and variable airflow obstruction and airway hyperresponsiveness, but provide support for the concept that airway hyperresponsiveness and variable airflow obstruction are causally related to the presence of trypsinase positive mast cells in the airway smooth muscle. We have shown that patients with non-eosinophilic asthma have a significantly reduced short-term response to inhaled cortico-steroids than those with eosinophilic asthma. Longer larger studies are required to determine whether inhaled corticosteroids can be safely withdrawn in patients with this asthma phenotype.

ACKNOWLEDGEMENTS

The authors thank Natalie Neale and Will Monterio who assisted in the processing of bronchial biopsy and induced sputum samples.

Further information is given in the online supplement available at http://thorax.bmj.com/supplemental.

Authors’ affiliations

Mike Berry, Angela Morgan, Dominick E Shaw, Deborah Parker, Ruth Green, Christopher Brightling, Peter Bradding, Andrew J Wardlaw, Ian D Pavord, Institute for Lung Health, Glenfield Hospital, Leicester, UK

This study was sponsored by a project grant from Asthma UK. The mometasone inhalers were a generous gift from Schering-Plough who had no role in the study.

Competing interests: None.

REFERENCES

2 Aas K. Heterogeneity of bronchial asthma. Sub-populations—or different stages of the disease. Allergy 1981;36:3–14.
4 Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against an "attractive" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996;154:1497–504.
Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma

Mike Berry, Angela Morgan, Dominick E Shaw, Deborah Parker, Ruth Green, Christopher Brightling, Peter Bradding, Andrew J Wardlaw and Ian D Pavord

Thorax 2007 62: 1043-1049 originally published online March 13, 2007
doi: 10.1136/thx.2006.073429

Updated information and services can be found at:
http:// thorax.bmj.com/content/62/12/1043

These include:

References

This article cites 24 articles, 6 of which you can access for free at:
http:// thorax.bmj.com/content/62/12/1043#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Asthma (1782)
Drugs: respiratory system (526)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http:// journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/